CRISPR gains as FDA panel completes review of gene therapy

Crispr Therapeutics AG

01/11/2023 10:33

** U.S.-listed shares of CRISPR Therapeutics  CRSP.O  up
~17% at $45.50 before the bell 
    ** Late on Tuesday, a panel of advisers to U.S. Food and
Drug Administration recommended that CRSP and partner Vertex
Pharmaceuticals  VRTX.O  assess potential safety risks of their
sickle cell disease gene therapy after approval 
    ** The advisory panel meeting gives greater confidence in
approval of the therapy called exa-cel - Jefferies
    ** Adds, feedback from meeting could indicate post-marketing
requirements and details on prescription label  
    ** VRTX has proposed a 15-year follow up of patients to
evaluate its safety outcomes, if therapy is approved
    ** FDA's decision on the use of the therapy expected by Dec.
8.
    ** Stock down 5% this year, as of last close

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))